Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

Eosinophilic esophagitis (EoE) is a chronic esophageal ... must be made on both clinical and histological grounds. Effective treatments rely on steroids and dietary exclusions.

Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Apogee Therapeutics, Inc.’s APGE share price has surged by 5.14%, which has investors questioning if this is right time to ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Cedars-Sinai researchers have developed a novel nutritional formula, mBiota Elemental, a palatable elemental diet (PED) that ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.

Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 5.46%, which has investors questioning if this is right time ...